This trial is testing a new drug to see if it is better than placebo at treating aGVHD, a serious complication from stem cell transplants.
1 Primary · 2 Secondary · Reporting Duration: Day 99
Experimental Treatment
Non-Treatment Group
200 Total Participants · 2 Treatment Groups
Primary Treatment: Itolizumab · Has Placebo Group · Phase 3
Age Any Age · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: